Jiang Chao, Xu Yong-Cheng, Zhang Wen, Pan Wen, Chao Xu
The Third Department of Neurology, The Second Affiliated Hospital of Xi'an Medical University, Xi'an.
Department of Emergency, Longhua Hospital Shanghai University of Traditional Chinese Medicine.
Medicine (Baltimore). 2020 Jun 5;99(23):e20534. doi: 10.1097/MD.0000000000020534.
We designed this study to assess the effects and safety of Buyang-Huanwu Decoction (BYHWD) for the treatment of patients with acute ischemic stroke (AIS).
Electronic databases of Cochrane Library, EMBASE, MEDLINE, CINAHL, PsycINFO, Scopus, Allied and Complementary Medicine Database, VIP Database, and China National Knowledge Infrastructure will be comprehensively and systematically searched from initial time of each electronic database to the present without limitations of language and publication status. Randomized controlled trials on BYHWD alone against any other interventions for the treatment of AIS will be included. All process of study selection, data collection, and methodological quality assessment will be independently undertaken by 2 investigators. Cochrane risk of bias tool and RevMan 5.3 software will be utilized for the performance of methodological quality assessment and statistical analysis, respectively.
This study will summarize most recent high quality evidence on investigating the effects and safety of BYHWD alone against any other interventions for the treatment of patients with AIS.
The findings of this study will provide helpful evidence for the clinical practice for patients with AIS using BYHWD, as well as the relevant future researches.Study registration number: INPLASY202040169.
我们设计本研究以评估补阳还五汤(BYHWD)治疗急性缺血性卒中(AIS)患者的疗效和安全性。
将全面、系统地检索Cochrane图书馆、EMBASE、MEDLINE、CINAHL、PsycINFO、Scopus、联合与补充医学数据库、维普数据库和中国知网的电子数据库,检索时间从各电子数据库创建之初至当前,不受语言和出版状态限制。纳入仅使用补阳还五汤与其他任何干预措施治疗AIS的随机对照试验。研究筛选、数据收集和方法学质量评估的所有过程将由2名研究者独立进行。分别使用Cochrane偏倚风险工具和RevMan 5.3软件进行方法学质量评估和统计分析。
本研究将总结关于单独使用补阳还五汤与其他任何干预措施治疗AIS患者的疗效和安全性的最新高质量证据。
本研究结果将为补阳还五汤治疗AIS患者的临床实践以及未来相关研究提供有益证据。研究注册号:INPLASY202040169。